Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase–mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARγ agonist that improves insulin sensitivity, on lipoprotein metabolism in patients with T2DM. Pio treatment reduced TG levels by increasing the fractional clearance rate (FCR) of VLDL TGs from the circulation, without changing direct removal of VLDL particles. This indicated increased lipolysis of VLDL TGs during Pio treatment, a mechanism supported by our finding of increased plasma LPL mass and decreased levels of plasma apoC-III. Lower apoC-III levels were due to reduced apoC-III PRs. We saw no effects of Pio on the PR of either VLDL TG or VLDL apoB. Thus, Pio, a PPARγ agonist, reduced VLDL TG levels by increasing LPL mass and inhibiting apoC-III PR. These 2 changes were associated with an increased FCR of VLDL TGs, almost certainly due to increased LPL-mediated lipolysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 2×
“gene expression is suppressed by PPARα agonists (67), possibly via direct binding of activated PPARα, in a nonproductive manner, to a hepatocyte nuclear factor-4 site in the apoC-III promoter (68, 69).”
BackgroundInsulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Self-citationSchoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173 · cited 1×
“LPL is a PPARγ-responsive gene (56), and the PPARγ agonist troglitazone has been demonstrated to increase postheparin plasma LPL activity (57) and both preheparin (58) and postheparin (59) LPL mass in subjects with diabetes and/or insulin resistance.”
BackgroundAn Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 2×
“ApoA-V is a recently identified apolipoprotein that appears to play an important role in TG metabolism (21), and several studies have shown that polymorphisms in the apoA-V gene are associated with hypertriglyceridemia (21, 78).”
BackgroundSHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855 · cited 1×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
ResultShimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13656 · Cited by 793 · cited 2×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
BackgroundResultLife without white fat: a transgenic mouse
Moitra, J., Mason, M. M., Olive, M., Krylov, D., Gavrilova, O., Marcus-Samuels, B., Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., et al. (1998) · Genes & Development · doi:10.1101/gad.12.20.3168 · Cited by 782 · cited 1×
“Studies in ob/ob and db/db mice (86), A-ZIP total lipodystrophic mice (87), and brown adipose tissue–deficient (BATless) (88) mice, all models of insulin resistance, have demonstrated increased hepatic expression of PPARγ and increased hepatic lipogenesis.”
BackgroundMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726 · cited 1×
“Troglitazone (12), Rosi (53), and Pio (13) have all been shown to have modest effects on the ability of insulin to suppress hepatic glucose production, but effects of TZDs on hepatic lipid metabolism are less well described.”
BackgroundGavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
Vidal-Puig, A., Jimenez-Liñan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S., & Moller, D. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118703 · Cited by 655 · cited 1×
“Studies in ob/ob and db/db mice (86), A-ZIP total lipodystrophic mice (87), and brown adipose tissue–deficient (BATless) (88) mice, all models of insulin resistance, have demonstrated increased hepatic expression of PPARγ and increased hepatic lipogenesis.”
Background
Research works printed but not linked: 3
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- Diraison, 1998, Am. J. Physiol., 274, E321
- Melish, 1980, Am. J. Physiol., 239, E354
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationAdiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“TZDs decrease adipocyte inflammation and increase secretion of adiponectin, enhance clearance of VLDL triglyceride (Nagashima et al., 2005), improve insulin-mediated suppression of lipolysis (Mayerson et al., 2002), and lower rates of post-prandial fatty acid turnover (Miles et al., 2003).”
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
“Some evidence suggests that pioglitazone lowers triglycerides by enhancing the triglyceride fractional catabolic rate rather than decreasing hepatic production (51).”
BackgroundEndocrine fibroblast growth factors 15/19 and 21: from feast to famine
Potthoff, M. J., Kliewer, S. A., & Mangelsdorf, D. J. (2012) · Genes & Development · doi:10.1101/gad.184788.111 · Cited by 442
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418
Self-citationApolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025253 · Cited by 240
Self-citationPeroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Jay, M., & Ren, J. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802067 · Cited by 196
“The PPAR� agonist pioglitazone decreases plasma triglycerides through increasing the fractional clearance rate of VLDL triglycerides, increasing lipoprotein lipase mass and lowering apoC-III [ 36 ].”
BackgroundThe Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
Targeting fatty acid metabolism to improve glucose metabolism
Stinkens, R., Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2015) · Obesity Reviews · doi:10.1111/obr.12298 · Cited by 183
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
“PPAR agonists Inhibit apoC-III transcription (from –20% up to –90%); reduce apoC-III secretion and plasma TG levels (–33%) [34,94–97]”
BackgroundPioglitazone: A Review of its Use in Type 2 Diabetes Mellitus
Waugh, J., Keating, G. M., Plosker, G. L., Easthope, S., & Robinson, D. M. (2006) · Drugs · doi:10.2165/00003495-200666010-00005 · Cited by 180
“[32] tes,[22-24] pioglitazone 30–45 mg/day for 16 weeks In addition, neointimal tissue proliferation after reduced TG levels by 22–31%.”
Deeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., & on behalf of the GLAI Study Investigators (2007) · Diabetes Care · doi:10.2337/dc06-1903 · Cited by 179
Szapary, P. O., Bloedon, L. T., Samaha, F. F., Duffy, D., Wolfe, M. L., Soffer, D., Reilly, M. P., Chittams, J., & Rader, D. J. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000195790.24531.4f · Cited by 162
“Waist circumference (meanSD), inches 42 (5.5) 41 (4.2) Body fat, n (%) 34 (11) 35 (13) SBP (meanSD), mm Hg 129 ( 14 ) 130 (12) DBP (meanSD), mm Hg 77 (8) 79 (8) Fasting HDL-C (meanSD), mg/dL 37 (6) 36 (5) Fasting TG (median interquartile range), mg/dL 183 (115 to 248) 193 (130 to 248) Fasting glucose (meanSD), mg/dL 8…”
InfluentialWatts, G. F., Chan, D. C., Somaratne, R., Wasserman, S. M., Scott, R., Marcovina, S. M., & Barrett, P. H. R. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy122 · Cited by 151
Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease
Kostrzewski, T., Cornforth, T., Snow, S. A., Ouro-Gnao, L., Rowe, C., Large, E. M., & Hughes, D. J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i2.204 · Cited by 149
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
“and that Angptl4 increases abundance of monomeric LPL in preheparin plasma (our unpublished data), it can be speculated that upregulation of Angptl4 may also account for the observed increase in plasma preheparin LPL levels in subjects treated with pioglitazone [108].”
InfluentialTiffin, N. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl381 · Cited by 145
Phytotherapy in diabetes: Review on potential mechanistic perspectives
El-Abhar, H. S., & Schaalan, M. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.176 · Cited by 145
Bajaj, M., Suraamornkul, S., Hardies, L. J., Glass, L. C., Musi, N., & DeFronzo, R. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0698-9 · Cited by 154
“In contrast, PIO does not alter APOA5 expression in patients with type 2 diabetes [ 36 ].”
BackgroundMethodInfluentialThe Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 153
Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., & Plutzky, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.055 · Cited by 145
“In clinical studies, pioglitazone induces LPL expression and also decreases the natural LPL inhibitor apoCIII (44, 90 ), further supporting possible indirect PPAR activation through increased VLDL hydrolysis.”
Samaha, F. F., Szapary, P. O., Iqbal, N., Williams, M. M., Bloedon, L. T., Kochar, A., Wolfe, M. L., & Rader, D. J. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000200136.56716.30 · Cited by 130
Packard, C. J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236367.42755.c1 · Cited by 127
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127
Xiong, Z., Chan, S. L., Zhou, J., Vong, J. S. L., Kwong, T. T., Zeng, X., Wu, H., Cao, J., Tu, Y., Feng, Y., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328364 · Cited by 131
Dixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 125
Pioglitazone in the treatment of NASH: the role of adiponectin
Gastaldelli, A., Harrison, S., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 113
Khetarpal, S. A., Zeng, X., Millar, J. S., Vitali, C., Somasundara, A. V. H., Zanoni, P., Landro, J. A., Barucci, N., Zavadoski, W. J., Sun, Z., et al. (2017) · Nature Medicine · doi:10.1038/nm.4390 · Cited by 108
Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 103
Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
Reyes-Soffer, G., Sztalryd, C., Horenstein, R. B., Holleran, S., Matveyenko, A., Thomas, T., Nandakumar, R., Ngai, C., Karmally, W., Ginsberg, H. N., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311476 · Cited by 97
Self-citationAn ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Millar, J. S., Reyes-Soffer, G., Jumes, P., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80025 · Cited by 89
Self-citationThe metabolism of lipoprotein (a): an ever-evolving story
Reyes-Soffer, G., Ginsberg, H. N., & Ramakrishnan, R. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r077693 · Cited by 88
“Studies of the kinetics of Lp(a) isolated in the densities of VLDL, IDL, LDL, and HDL will provide information crucial to addressing several of the questions regarding the origin and clearance of Lp(a), but this will require efficient recovery of Lp(a) from isolated fractions, something that has eluded investigators t…”
BackgroundSelf-citationKhattab, M. A., Emad, M., Abdelaleem, A., Eslam, M., Atef, R., Shaker, Y., & Hamdy, L. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02171.x · Cited by 92
Pioglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006060.pub2 · Cited by 87
Parks, E. J., & Hellerstein, M. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600018-jlr200 · Cited by 85
HDL Cholesterol: Physiology, Pathophysiology, and Management
Link, J. J., Rohatgi, A. K., & de Lemos, J. A. (2007) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2007.01.004 · Cited by 95
Regulation of chylomicron production in humans
Xiao, C., & Lewis, G. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.019 · Cited by 91
Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., Lundbom, J., Lundbom, N., Matikainen, N., Kahri, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305614 · Cited by 72
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Wilding, J. P. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01601.x · Cited by 73
Chan, D. C., Barrett, P. H. R., Ooi, E. M. M., Ji, J., Chan, D. T., & Watts, G. F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1457 · Cited by 66
Ivanova, E. A., Parolari, A., Myasoedova, V. A., Melnichenko, A. А., Bobryshev, Y. V., & Orekhov, A. N. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.05.004 · Cited by 73
“dioprotective effects of rosiglitazone had been confirmed in a study on diabetic rats [36].”
BackgroundEmerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Geldenhuys, W. J., Lin, L., Darvesh, A. S., & Sadana, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.007 · Cited by 64
Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000199815.46720.ca · Cited by 64
Ginsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64
Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 62
Mechanism of intestinal lipoprotein overproduction in insulin resistant humans
Duez, H., Pavlic, M., & Lewis, G. F. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.013 · Cited by 67
Chan, D. C., Watts, G. F., Ng, T. W. K., Yamashita, S., & Barrett, P. H. R. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02019.x · Cited by 60
PPARγ deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects
Kraakman, M. J., Liu, Q., Postigo-Fernandez, J., Ji, R., Kon, N., Larrea, D., Namwanje, M., Fan, L., Chan, M., Área-Gómez, E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98709 · Cited by 60
Thiazolidinediones and the liver in humans
Yki-Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 59
Majali, K. A., Cooper, M. B., Staels, B., Luc, G., Taskinen, M., & Betteridge, D. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0092-4 · Cited by 58
“protein C-III levels, although this is not thought to be mediated through the PPAR-γ receptor [36].”
BackgroundEleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“Pioglitazone on the other hand increases HDL cholesterol and decreases fasting and postprandial triglyceride concentrations [82-85].”
BackgroundParhofer, K. G., & Barrett, P. H. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600013-jlr200 · Cited by 56
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 66
Self-citationAntidiabetic Effect ofMorinda citrifolia(Noni) Fermented byCheonggukjangin KK-AyDiabetic Mice
Lee, S., Park, S., Hwang, J., Yi, S.-H., Nam, Y., & Lim, S. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/163280 · Cited by 58
“PPAR-γ agonists also significantly decrease total cholesterol and triglyceride in type 2 diabetic patients and model animals [36, 37].”
BackgroundChappuis, B., Braun, M., Stettler, C., Allemann, S., Diem, P., Lumb, P. J., Wierzbicki, A. S., James, R. W., & Christ, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.715 · Cited by 54
“ApoC-II stimulates LPL activity while apoC-III inhibits it, and both are found on VLDL particles [31,32].”
BackgroundGries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 68
Pathogenesis and Management of the Dyslipidemia of the Metabolic Syndrome
Raal, F. J. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0079 · Cited by 58
Targeting host factors: A novel rationale for the management of hepatitis C virus
Khattab, M. A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3472 · Cited by 60
Pavlic, M., Valéro, R., Duez, H., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.169383 · Cited by 51
Deeg, M. A., & Tan, M. H. (2008) · PPAR Research · doi:10.1155/2008/520465 · Cited by 49
“This hypothesis is supported by the observation that pioglitazone increases the lipolysis of VLDL triglycerides without affecting the removal of VLDL particles [22].”
InfluentialJain, R., Osei, K., Kupfer, S., Perez, A. T., Zhang, J., & Lannon, M. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.10.1388 · Cited by 47
Souza-Tavares, H., Miranda, C. S., Vasques‐Monteiro, I. M. L., Sandoval, C., Santana-Oliveira, D. A., Silva-Veiga, F. M., Fernandes‐da‐Silva, A., & Souza‐Mello, V. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i26.4136 · Cited by 54
Algenstaedt, P., Stumpenhagen, A., & Westendorf, J. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/3565427 · Cited by 69
“It also decreases the output of glucose from liver cells [34].”
BackgroundHigh postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria
Tentolouris, N., Stylianou, A., Lourida, E. S., Perrea, D. N., Kyriaki, D., Papavasiliou, E. C., Tselepis, A. D., & Katsilambros, N. L. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600367-jlr200 · Cited by 48
“Poor glycemic control decreases (8, 12, 30), whereas treatment with glitazones increases, LPL activity ( 16 ).”
BackgroundTero-Vescan, A., Degens, H., Matsakas, A., Ștefănescu, R., Ősz, B. E., & Slevin, M. (2025) · Pharmaceuticals · doi:10.3390/ph18081222 · Cited by 44
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 42
Beysen, C., Murphy, E. J., Nagaraja, H. N., Decaris, M. L., Riiff, T. J., Fong, A., Hellerstein, M. K., & Boyle, P. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800165-jlr200 · Cited by 41
Hiuge-Shimizu, A., Maeda, N., Hirata, A., Nakatsuji, H., Nakamura, K., Okuno, A., Kihara, S., Funahashi, T., & Shimomura, I. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.221747 · Cited by 38
Hayashi, T., Hirano, T., Yamamoto, T., Ito, Y., & Adachi, M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.014 · Cited by 38
“Nagashima et al [21] recently reported that pioglitazone, an insulin sensitizer, decreases apoC-III production in type 2 diabetic patients, and they explained this change as being due to increased VLDL catabolism.”
BackgroundGupta, A. K., Smith, S. R., Greenway, F. L., & Bray, G. A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00965.x · Cited by 37
Spanheimer, R. G., Betteridge, D. J., Tan, M. H., Ferrannini, E., & Charbonnel, B. H. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.03.023 · Cited by 44
Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., & Ferrannini, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90960.2008 · Cited by 36
Pioglitazone increases non-esterified fatty acid clearance in upper body obesity
Shadid, S., & Jensen, M. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0051-0 · Cited by 39
“A recent report showed that pioglitazone treatment of type 2 diabetes lowered VLDL triglyceride concentrations, did not increase hepatic VLDL triglyceride production, but did increase VLDL triglyceride clearance [43].”
BackgroundTargeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 35
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 47
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 35
“Nagashima et al. (2005) carried out a stable isotope study in type 2 diabetes investigating the effect of pioglitazone on the kinetics of VLDL, IDL, and LDL-apoB-100.”
BackgroundLee, K. W., Cho, J. G., Kim, C. M., Kang, A. Y., Kim, M., Ahn, B. Y., Chung, S. S., Lim, K.-H., Baek, K.-H., Sung, J.-H., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496331 · Cited by 33
“The chronic treatment of pioglitazone, a PPAR agonist, has been known to reduce VLDL TG levels by increasing the expression of lipoprotein lipase (36, 37).”
BackgroundComplex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans
Reyes‐Soffer, G., Moon, B. C., Hernández‐Ono, A., Dionizovik-Dimanovski, M., Jimenez, J., Obunike, J. C., Thomas, T. A., Ngai, C. I., Fontanez, N., Donovan, D. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2195 · Cited by 38
Self-citationLiu, C., Lee, T.-H., Lin, Y., Sung, P., Wei, Y., & Li, Y. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0979-x · Cited by 41
Kim, M., Wang, F., Puthanveetil, P., Kewalramani, G., Innis, S. M., Marzban, L., Steinberg, S. F., Webber, T. D., Kieffer, T. J., Abrahani, A., et al. (2009) · Diabetes · doi:10.2337/db09-0681 · Cited by 33
“Interestingly, drugs such as pioglitazone that are known to decrease caspase-3 (46) have been reported to reduce circulating triglycerides (47,48) by increasing LPL in humans (49) and to increase the myocardial content of lipids in rats fed a high-fat diet (50).”
BackgroundThe cardiovascular effects of the thiazolidinediones: a review of the clinical data
Kelly, A. S., & Bank, A. J. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.03.006 · Cited by 34
“Although not well described, mechanisms responsible for the lipid improvements may be related to changes in lipoprotein lipase-mediated triglyceride clearance (Nagashima et al., 2005).”
BackgroundBajpeyi, S., Pasarica, M., Conley, K. E., Newcomer, B. R., Jubrias, S. A., Gamboa, C., Murray, K. B., Sereda, O., Sparks, L. M., & Smith, S. R. (2016) · Metabolism · doi:10.1016/j.metabol.2016.11.016 · Cited by 33
Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice
Peng, J., Huan, Y., Jiang, Q., Sun, S., Jia, C., & Shen, Z. (2014) · PPAR Research · doi:10.1155/2014/538183 · Cited by 32
The role of pioglitazone in modifying the atherogenic lipoprotein profile
Hanefeld, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01048.x · Cited by 31
Involvement of adipose tissues in the early hypolipidemic action of PPARγ agonism in the rat
Laplante, M., Festuccia, W. T., Soucy, G., Gélinas, Y., Lalonde, J., & Deshaies, Y. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00761.2006 · Cited by 32
Matsuo, K., Arai, H., Muto, K., Fukaya, M., Sato, T., Mizuno, A., Sakuma, M., Yamanaka‐Okumura, H., Sasaki, H., Yamamoto, H., et al. (2007) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.40.234 · Cited by 29
Chan, D. C., Nguyen, M. N., Watts, G. F., Ooi, E. M. M., & Barrett, P. H. R. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28422 · Cited by 31
HDL metabolism in context: looking on the bright side
Watts, G. F., Barrett, P. H. R., & Chan, D. C. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328306596d · Cited by 34
Ramakrishnan, R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600302-jlr200 · Cited by 28
Self-citationPPARγ Agonists Attenuate Trigeminal Neuropathic Pain
Lyons, D. N., Zhang, L., Danaher, R. J., Miller, C. S., & Westlund, K. N. (2017) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000509 · Cited by 32
Rashid, S., Patterson, B. W., & Lewis, G. F. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600008-jlr200 · Cited by 31
Zhang, L., Kamanna, V. S., Ganji, S. H., Xiong, X., & Kashyap, M. L. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m004481 · Cited by 26
“The effects of pioglitazone to reduce triglycerides are mainly shown to be mediated by increased lipoprotein lipase expression through the activation of PPARγ, and decrease plasma apoCIII, an inhibitor for lipoprotein lipase-mediated lipolysis [15].”
Background
Metadata
- Authors
- Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., & Ginsberg, H. N.
- Affiliations
- Columbia University (US)
- Cornell University (US)
- Montreal Clinical Research Institute (CA)
- Corresponding author
- Ginsberg, Henry N.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-04-01
- Volume
- 115
- Issue
- 5
- Pages
- 1323-1332
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1070635
- OpenAlex
- W2132525699
- Cited by
- 201
- References
- 104
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- Takeda Pharmaceuticals North America
- Deutsches Krebsforschungszentrum
- National Institutes of Health (RR-00645)
- National Heart, Lung, and Blood Institute (HL55368)
- National Center for Research Resources (RR 00645, M01RR000645)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, PPARγ agonists, type 2 diabetes, lipoprotein metabolism, VLDL triglycerides, lipoprotein lipase, apolipoprotein C-III, triglyceride clearance, lipolysis, insulin sensitivity
- MeSH terms
- Pioglitazone, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Female, Humans, Hypoglycemic Agents, Insulin, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Triglycerides, Intercellular Signaling Peptides and Proteins, Thiazolidinediones, PPAR gamma, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.